|
Deferred Research And Development Arrangement (Details) (USD $)
|
0 Months Ended | 3 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 07, 2012
|
Dec. 04, 2012
|
Mar. 31, 2011
|
Jan. 19, 2011
|
Jun. 30, 2010
|
Feb. 12, 2010
|
Oct. 23, 2009
|
Sep. 21, 2009
|
Jun. 05, 2009
|
Mar. 20, 2008
|
Dec. 18, 2007
|
May 13, 2006
|
Dec. 02, 2005
|
Aug. 08, 2005
|
May 10, 2001
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Mar. 31, 2013
Rexgene [Member]
|
Dec. 31, 2003
Rexgene [Member]
|
Dec. 31, 2012
Rexgene [Member]
|
Jan. 19, 2011
Teva Pharmaceutical Industries, Ltd. [Member]
|
Sep. 21, 2009
Teva Pharmaceutical Industries, Ltd. [Member]
|
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Dec. 31, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
Nov. 27, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
|
| Research and development arrangement, one-time fee | $ 1,500,000 | ||||||||||||||||||||||||
| Reduction of research and development expenses | 134,621 | 18,750 | |||||||||||||||||||||||
| Deferred Research and Development Arrangement | 1,472,629 | 1,626,000 | 731,250 | 750,000 | 741,379 | 876,000 | |||||||||||||||||||
| Royalties paid, percentage of net sales | 3.00% | ||||||||||||||||||||||||
| Stock Issued During Period, Shares, Issued for Cash | 2,083,333 | 19,130,435 | 8,333,333 | 2,334,515 | 6,666,667 | 300,000 | 6,072,383 | 3,102,837 | 2,857,143 | 642,858 | 4,857,159 | 3,850,000 | 650,000 | 4,175,000 | 3,600,000 | 2,334,515 | 3,102,837 | 7,520,685 | |||||||
| Stock Issued During Period, Value, Issued for Cash | 750,000 | 3,950,000 | 3,500,000 | 1 | 3,950,000 | 3,500,000 | |||||||||||||||||||
| Restricted Cash and Cash Equivalents, Noncurrent | $ 957,180 | $ 1,091,801 | $ 2,000,000 | $ 926,000 | |||||||||||||||||||||